Jane Qiu, a freelance science writer based in Beijing, published an overview of her efforts to investigate the lab-leak theory for the origin of COVID-19. In another update, the FDA’s Vaccines and Related Biological Products Advisory Committee is scheduled to meet on February 15 to discuss an amended Emergency Use Authorization for the Pfizer-BioNTech COVID-19 vaccine for children 6 months through 4 years of age.

Mersana Therapeutics signed a research and licensing deal with Janssen Biotech to access each other’s proprietary technology in discovering new antibody-drug conjugates (ADCs) for three cancer targets. 

After a U.S. District Court judge ruled that the U.S. Food and Drug Administration must begin disclosing data surrounding the approval of COVID-19 vaccines within a span of eight months, Pfizer hopes to step in to ensure that no trade secrets are disclosed when the regulatory agency begins to share that information.

Johnson & Johnson on Jan. 25 forecast as much as $3.5 billion in sales of the company’s COVID-19 vaccine in 2022, a 46% jump for the shot that has fared poorly compared to rivals. Additionally, J&J plans to take a more aggressive stance on deals for the company’s medical device unit.

A safety panel of the European drug regulator on January 14 recommended adding a rare spinal inflammation called transverse myelitis as a side effect of AstraZeneca’s COVID-19 vaccine.

A Johnson and Johnson COVID-19 vaccine booster shot is 85 percent effective in protecting against being hospitalized by the Omicron variant for 1-2 months after the shot is received, the head of South Africa’s Medical Research Council (SAMRC) said on January 14.

The U.S. Food and Drug Administration added another warning to the regulatory agency’s fact sheet for Johnson & Johnson’s COVID-19 vaccine. In other news, as the Omicron variant rips through the United States, top health officials have noted that the variant is so contagious that if you come into contact with it, you are likely to catch it.

The U.S. Food and Drug Administration on January 11 amended the fact sheet for Johnson & Johnson’s COVID-19 vaccine to include a rare risk of immune thrombocytopenia, a bleeding disorder.

The Janssen Pharmaceutical Companies of Johnson & Johnson submitted a Biologics License Application (BLA) for teclistamab to the U.S. Food and Drug Administration for relapsed or refractory multiple myeloma.

J&J’s Janssen Pharmaceutical ended a collaboration with San Francisco’s Theravance Biopharma after a disappointing performance from a drug the two companies were developing together.